Communiqué de presse : Le CHMP recommande l'approbation de Dupixent dans l'UE pour le traitement des patients atteints de BPCO
May 31, 2024 01:05 ET
|
Sanofi - Aventis Groupe
Le CHMP recommande l'approbation de Dupixent dans l'UE pour le traitement des patients atteints de BPCO Recommandation pour les adultes atteints d’une BPCO non contrôlée avec éosinophilie...
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
May 31, 2024 01:05 ET
|
Sanofi - Aventis Groupe
Dupixent recommended for EU approval by the CHMP to treat patients with COPD Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3...
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
May 31, 2024 01:05 ET
|
Regeneron Pharmaceuticals, Inc.
Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved...
Global Dialysis Chairs Market Size To Exceed USD 130.9 Million By 2033 | CAGR Of 4.47%
May 31, 2024 01:00 ET
|
SPHERICAL INSIGHTS LLP
New York, United States , May 31, 2024 (GLOBE NEWSWIRE) -- The Global Dialysis Chairs Market Size is to Grow from USD 84.5 Million in 2023 to USD 130.9 Million by 2033, at a Compound Annual Growth...
Communiqué de presse : Point d’actualité sur l’examen prioritaire de la FDA relatif au Dupixent pour le traitement de la BPCO avec inflammation de type 2
May 31, 2024 01:00 ET
|
Sanofi - Aventis Groupe
Point d’actualité sur l’examen prioritaire de la FDA relatif au Dupixent pour le traitement de la BPCO avec inflammation de type 2 Paris et Tarrytown (New York), le 31 mai 2024. La Food and...
Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation
May 31, 2024 01:00 ET
|
Sanofi - Aventis Groupe
Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation Paris and Tarrytown, NY May 31, 2024. The US Food and Drug Administration (FDA) has...
Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024
May 31, 2024 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, May 31, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric...
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
May 31, 2024 01:00 ET
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has extended by...
Clip Money Inc. Reports First Quarter 2024 Results
May 30, 2024 22:37 ET
|
Clip Money Inc
TORONTO, May 30, 2024 (GLOBE NEWSWIRE) -- Clip Money, Inc. (“Clip” or “Company”) (TSXV:CLIP) (OTCQB:CLPMF), a company that operates a multi-bank self-service deposit system for businesses, is...
CloudMD Reports First Quarter 2024 Results
May 30, 2024 21:56 ET
|
CloudMD
CloudMD Reports First Quarter 2024 Results